Ultragenyx Pharmaceutical Inc. Share Price Today: Live Updates & Key Insights
Ultragenyx Pharmaceutical Inc. share price today is $19.87, up -2.69%. The stock opened at $20.26 against the previous close of $20.42, with an intraday high of $20.645 and low of $19.86.
Ultragenyx Pharmaceutical Inc. Share Price Chart
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. Share Price Performance
Ultragenyx Pharmaceutical Inc. Institutional Holdings
Ultragenyx Pharmaceutical Inc. Market Status
Ultragenyx Pharmaceutical Inc. Fundamentals
Market Cap 1920.03 M
PB Ratio 247.6984
PE Ratio 0.0
Enterprise Value 1275.07 M
Total Assets 1532.00 M
Volume 3797567
Ultragenyx Pharmaceutical Inc. Company Financials
About Ultragenyx Pharmaceutical Inc. & investment objective
Company Information Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Organisation Biotechnology
Employees 1371
Industry Biotechnology
CEO Dr. Emil D. Kakkis M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Ultragenyx Pharmaceutical Inc. FAQs
What is the share price of Ultragenyx Pharmaceutical Inc. today?
The current share price of Ultragenyx Pharmaceutical Inc. is $19.87.
Can I buy Ultragenyx Pharmaceutical Inc. shares in India?
Yes, Indian investors can buy Ultragenyx Pharmaceutical Inc. shares by opening an international trading and demat account with Motilal Oswal.
How to buy Ultragenyx Pharmaceutical Inc. shares in India?
You can easily invest in Ultragenyx Pharmaceutical Inc. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Ultragenyx Pharmaceutical Inc. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Ultragenyx Pharmaceutical Inc..
Can I buy fractional shares of Ultragenyx Pharmaceutical Inc.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. has a market cap of $1920.03 M.
In which sector does Ultragenyx Pharmaceutical Inc. belong?
Ultragenyx Pharmaceutical Inc. operates in the Biotechnology sector.
What documents are required to invest in Ultragenyx Pharmaceutical Inc. stocks?
To invest, you typically need:
What is the PE and PB ratio of Ultragenyx Pharmaceutical Inc.?
The PE ratio of Ultragenyx Pharmaceutical Inc. is N/A and the PB ratio is 247.70.